Hims & Hers Stock (HIMS) Plunge: A Contrarian Opportunity Emerges
Hims & Hers Health shares cratered 30% in a single session after Novo Nordisk severed its partnership with the telehealth provider. Yet beneath the panic selling, a compelling narrative unfolds.
Retail traders flooded Interactive Brokers with buy orders, propelling HIMS into the platform's top-traded equities - outperforming tech behemoths. Options activity reveals pronounced bullish positioning, with speculators betting on mean reversion.
The stock's 75% year-to-date gain before the collapse suggests underlying strength. Analysts highlight three pillars supporting the bull case: expanding subscriber rolls, diversified product offerings, and structural tailwinds in digital healthcare.